Tolerability Issues During Long-Term Treatment with Antidepressants

References

• Weissman MM BM, Leaf PJ, Florio LP: The Epidemi-Hologic Catchment Area Study. Affective Disorders. In Robins LN and Regier DA eds. Psychiatric disorders in America. New York: The Free Press, 1991, pp. 53–80.
   Google Scholar
• Blazer DG, Kessler RC, McGonagle KA, Swartz MS: The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey. Am J Psychiatry 1994; 151(7):979–986.
   PubMed Web of Science ®Google Scholar
• Carta MG, Carpiniello B, Kovess V. Porcedda R, Zedda A, Rudas N: Lifetime prevalence of major depression and dysthymia: results of a community survey in Sardinia. Eur Neuropsychopharmacol 1995; 5(Suppl):103–107.
   Google Scholar
• Goldney RD, Fisher LJ, Wilson DH, Cheok F: Major depression and its associated morbidity and quality of life in a random, representative Australian community sample. Aust N Z J Psychiatry 2000; 34(6):1022–1029.
   PubMed Web of Science ®Google Scholar
• Zheng D, Macera CA, Croft JB, Giles WH, Davis D, Scott WK: Major depression and all-cause mortality among white adults in the United States. Ann Epide-miol 1997; 7(3):213–218.
   PubMed Web of Science ®Google Scholar
• Bruce ML, Leaf PJ, Rozal GP, Florio L, Hoff RA: Psychiatric status and 9-year mortality data in the New Haven Epidemiologic Catchment Area Study. Am J Psychiatry 1994; 151(5):716–721.
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER: The economic burden of depression in 1990. J Clin Psychiatry 1993; 54(11):405–418.
   PubMed Web of Science ®Google Scholar
• Keller MB, Klerman GL, Lavori PW, Coryell W, Endicott J, Taylor J: Long-term outcome of episodes of major depression. Clinical and public health signi-ficance. JAMA 1984; 252(6):788–792.
   Google Scholar
• Frank E, Kupfer DJ, Perel JM, Comes C, Jarrett DB, Mallinger AG, Thase ME, McEachran AB, Grochocin-ski VJ: Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47(12):1093–1099.
   Google Scholar
• Hirschfeld RM: Clinical importance of long-term antide-pressant treatment. Br J Psychiatry Suppl 2001; 42:S4–8.
   PubMedGoogle Scholar
• Fava M, Kaji J: Continuation and maintenance treat-ments of major depressive disorder. Psychiatr Ann 1994; 24:281–290.
   Google Scholar
• Depression in Primary Care. Clinical Practice Guidelines. Rockville, MD, US Dept Human Service, Agency for Health Care Policy and Research, 1993.
   Google Scholar
• Thase ME: Redefming antidepressant efficacy toward long-term recovery. J Chin Psychiatry 1999; 60 Suppl 6:15–19.
   PubMedGoogle Scholar
• Nierenberg AA: Long-term management of chronic depression. J Clin Psychiatry 2001; 62 Suppl 6:17–21.
   Google Scholar
• Sonawalla SB, Fava M: Severe depression: Is there a best approach? CNS Drugs 2001; 15(10):765–776.
   PubMed Web of Science ®Google Scholar
• Mueller TI, Leon AC, Keller MB, Solomon DA, Endi-cott J, Coryell W, Warshaw M, Maser JD: Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999; 156(7):1000–1006.
   PubMed Web of Science ®Google Scholar
• Kupfer DJ, Frank E, Perel JM, Comes C, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ: Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49(10):769–773.
   Google Scholar
• Zajecka J, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Tamura RN, Sundell KL, Michelson D, Beasley CM, Jr.: Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry 1999; 60(6):389–394.
   Google Scholar
• Katon W, von Korff M, Lin E, Bush T, Ormel J: Adequacy and duration of antidepressant treatment in primary care. Med Care 1992; 30(1):67–76.
   PubMedGoogle Scholar
• Lin EH, Von Korff M, Katon W, Bush T, Simon GE, Walker E, Robinson P: The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995; 33(1):67–74.
   PubMed Web of Science ®Google Scholar
• Lin EH, Simon GE, Katon WJ, Russo JE, Von Korff M, Bush TM, Ludman EJ, Walker EA: Can enhanced acute-phase treatment of depression improve long-term outcomes? A report of randomized trials in primary care. Am J Psychiatry 1999; 156(4):643–645.
   Google Scholar
• Fava M, Judge R, bog SL, Nilsson ME, Koke SC: Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000; 61(11):863–867.
   PubMed Web of Science ®Google Scholar
• Brown WA, Harrison W: Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 1995; 56(1):30–34.
   Google Scholar
• Thase ME, Blomgren SL, Birkett MA, Apter if, Tepner RG: Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997; 58(1):16–21.
   Web of Science ®Google Scholar
• Thase ME, Trivedi MH, Rush AJ: MAOIs in the contemporary treatment of depression. Neuropsy-chopharmacology 1995; 12(3):185–219.
   PubMed Web of Science ®Google Scholar
• Remick RA, Froese C, Keller FD: Common side effects associated with monoamine oxidase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13(3-4):497–504.
   Google Scholar
• Harrison WM RJ, Ehrhardt AA, Stewart JW, McGrath PJ, Ross D, Quitkin FM: Effects of antidepressant medication on sexual function: a controlled study. J Clin Psychopharmacol. 1986; 6(3):144–149.
   Google Scholar
• Zajecka JM: Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry 2000; 61 Suppl 2:20–25.
   PubMedGoogle Scholar
• Moss H: More cases of anorgasmia after MAOI treatment. Am J Psychiatry 1983; 140:266.
   PubMed Web of Science ®Google Scholar
• Fava M: Weight gain and antidepressants. J Clin Psychiatry 2000; 61 Suppl 11:37–41.
   PubMed Web of Science ®Google Scholar
• Guelfi JD, Payan C, Fermanian J, Pedarriosse AM, Manfredi R: Moclobemide versus clomipramine in endogenous depression. A double-blind randomised clinical trial. Br J Psychiatry 1992; 160:519–524
   PubMedGoogle Scholar
• Vaz-Serra A, Figueira ML, Firmino H, Albuquerque AJ, Jara JM, Pestana LC: Multicenter double-blind study of moclobemide and maprotiline. Clin Neurop-harmacol 1994; 17 Suppl 1:S38–49
   Google Scholar
• Philipp M, Kohnen R, Benkert 0: A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction. Int Clin Psychopharmacol 1993; 7(3-4):149–153.
   PubMed Web of Science ®Google Scholar
• Benazzi F: Serotonin syndrome with moclobemide-fluoxetine combination. Pharmacopsychiatry 1996; 29(4):162.
   Google Scholar
• Dingemanse J, Guentert T, Gieschke R, Stahl M: Modi-fication of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobe-mide. J Cardiovasc Pharmacol 1996; 28(6):856–861.
   Google Scholar
• Steffens DC, Krishnan KR, Helms MJ: Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 1997; 6(1):10–8.
   PubMedGoogle Scholar
• Glassman AH: Cardiovascular effects of antidepressant drugs: updated. Int Clin Psychopharmacol 1998; 13 Suppl 5:S25–30.
   PubMedGoogle Scholar
• Jefferson JW: A review of the cardiovascular effects and toxicity of tricyclic antidepressants. Psychosom Med 1975; 37(2):160–179.
   PubMed Web of Science ®Google Scholar
• Shipley JE, Kupfer DJ, Griffm SJ, Dealy RS, Coble PA, McEachran AB, Grochocinski VJ, Ulrich R, Perel JM: Comparison of effects of desipramine and ami-triptyline on EEG sleep of depressed patients. Psychopharmacology (Berl) 1985; 85(1):14–22.
   Google Scholar
• Bye C, Clubley M, Peck AW: Drowsiness, impaired performance and tricyclic antidepressants drugs. Br J Clin Pharmacol 1978; 6(2):155–162.
   Google Scholar
• Blackwell B, Stefopoulos A, Enders P. Kuzma R, Adolphe A: Anticholinergic activity of two tricyclic antidepressants. Am J Psychiatry 1978; 135(6):722–724.
   Google Scholar
• Mulsant BH, Pollock BG, Nebes RD, Miller MD, Lit-tle JT, Stack J, Houck PR, Bensasi S, Mazumdar S, Reynolds CF, 3rd: A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. J Clin Psychiatry 1999; 60 Suppl 20:16–20.
   PubMedGoogle Scholar
• Oslin DW, Streim JE, Katz IR, Smith BD, DiFilippo SD, Ten Have TR, Cooper T: Heuristic comparison of sertraline with nortriptyline for the treatment of depression in frail elderly patients. Am J Geriatr Psychiatry 2000; 8(2):141–149.
   Google Scholar
• Preskorn SH, Fast GA: Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effec-tiveness. J Clin Psychiatry 1991; 52 Supp1:23–33.
   Google Scholar
• Burke MJ, Preskorn SH: Therapeutic drug monitoring of antidepressants: Cost implications and relevance to clinical practice. Clin Pharmacokinet 1999; 37(2): 147–165.
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M: Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994; 151(7):1069–1072
   PubMed Web of Science ®Google Scholar
• Gerner R EW, Steuer J, Jarvik L: Treatment of geriatric depression with trazodone, imipramine, and placebo: A double-blind study. J Clin Psychiatry 1980; 41(6): 216–220.
   Google Scholar
• Anderson IM: Selective serotonin reuptake inhibitors versus tricyclic antidepressants. J Affective Disord 2000; 58(1):19–36.
   PubMed Web of Science ®Google Scholar
• Peretti S, Judge R, Hindmarch I: Safety and tolerability considerations: Tricyclic antidepressants versus, selec-tive serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000; 403:17–25.
   PubMedGoogle Scholar
• Anderson IM: Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58(1): 19–36.
   PubMed Web of Science ®Google Scholar
• Fava M, Rankin M: Sexual functioning and SSRIs. J Clin Psychiatry 2002; 63 Suppl 5:13–6; discussion 23–25.
   Google Scholar
• Masand PS, Gupta S: Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 1999; 7(2): 69–84.
   PubMed Web of Science ®Google Scholar
• Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum IF, Zajecka J, Sundell KL, Kim Y, Beasley CM, Jr.: Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999; 156(8): 1170–1176.
   Google Scholar
• Lewis-Hall FC, Wilson MG, Tepner RG, Koke SC: Fluoxetine vs. tricyclic antidepressants in women with major depressive disorder. J Womens Health 1997; 6(3):337–343.
   Google Scholar
• Montgomery SA: A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepres-sants in the treatment of major depression. Int Clin Psychopharmacol 2001; 16(3):169–178.
   PubMed Web of Science ®Google Scholar
• Kyle CJ, Petersen HE, Overo KF: Comparison of the tolerability and efficacy of citalopram and amitrip-tyline in elderly depressed patients treated in general practice. Depress Anxiety 1998; 8(4):147–153.
   Google Scholar
• Ottevanger EA: Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study. Encephale 1995; 21(4):317–321.
   Google Scholar
• Sussman N, Ginsberg DL, Bikoff J: Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry 2001; 62(4): 256–260.
   PubMed Web of Science ®Google Scholar
• Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Calcedo A, Carrasco JL, Ciudad J, Daniel E, De la Gandara J, Derecho J, Franco M, Gomez MJ, Macias JA, Martin T, Perez V, Sanchez JM, Sanchez S, Vicens E: SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997; 23(3):176–194.
   PubMed Web of Science ®Google Scholar
• Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL: A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry 1998; 10(4): 145–150.
   PubMedGoogle Scholar
• Aberg-Wistedt A, Agren H, Ekselius L, Bengtsson F, Akerblad AC: Sertraline versus paroxetine in major depression: clinical outcome after six months of con-tinuous therapy. J Clin Psychopharmacol 2000; 20(6): 645–652.
   Google Scholar
• Dording CM, Mischoulon D, Petersen TJ, Kornbluh R, Gordon J, Nierenberg AA, Rosenbaum JE, Fava M: The pharmacologic management of SSRI-induced side effects: A survey of psychiatrists. Ann Clin Psychiatry 2002; 14(3):143–147.
   PubMedGoogle Scholar
• Horst WD, Preskorn SH: Mechanisms of action and clinical characteristics of three atypical antidepres-sants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998; 51(3):237–254.
   PubMed Web of Science ®Google Scholar
• Harvey AT, Rudolph RL, Preskorn SH: Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000; 57(5):503–509.
   PubMed Web of Science ®Google Scholar
• Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT: A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998; 59(3):116–122.
   PubMed Web of Science ®Google Scholar
• Feighner JP: Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 1995; 56(12):574–579.
   PubMedGoogle Scholar
• Siepmann M, Muck-Weymann M, Joraschky P. Kirch W: The effects of reboxetine on autonomic and cognitive functions in healthy volunteers. Psychopharmacology (Berl) 2001; 157(2):202–207.
   Google Scholar
• Schatzberg AF: Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 2000; 61 Suppl 10:31–38.
   Google Scholar
• Hellerstein DJ, Batchelder S, Kreditor D, Fedak M: Bupropion sustained-release for the treatment of dysthymic disorder: an open-label study. J Clin Psychop-harmacol 2001; 21(3):325–329.
   Google Scholar
• Branconnier RJ, Cole JO, Ghazvinian S, Spera KF, Oxenkrug GE, Bass JL: Clinical pharmacology of bupropion and imipramine in elderly depressives. J Clin Psychiatry 1983; 44(5 Pt 2):130–133.
   Google Scholar
• Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA: A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998; 59(7):366–373.
   PubMed Web of Science ®Google Scholar
• Johnston JA, Lineberry CG, Ascher JA, Davidson J, Khayrallah MA, Feighner JP, Stark P: A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991; 52(11):450–456.
   PubMed Web of Science ®Google Scholar
• Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997; 53(4): 608–636.
   Google Scholar
• Baldwin DS, Hawley CJ, Mellors K: A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: Safety, tolerability and efficacy in continuation phase treatment. J Psychopharmacol 2001; 15(3): 161–165 .
   Google Scholar
• Cohn CK, Robinson DS, Roberts DL, Schwiderski UE, O'Brien K, Ieni JR: Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry 1996; 57 Suppl 2:15–18.
   PubMedGoogle Scholar
• Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J, Cohen M: Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: An open-label trial. J Clin Psychiatry 2001; 62(6):413–420.
   PubMedGoogle Scholar
• Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F: Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001; 62 Suppl 3:10–21.
   Google Scholar
• Lane RM: A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management. J Psychopharmacol 1997; 11(1):72–82.
   Google Scholar
• Michelson D, Bancroft J, Targum S, Kim Y, Tepner R: Female sexual dysfunction associated with antidepres-sant administration: a randomized, placebo-controlled study of pharmacologic intervention. Am J Psychiatry 2000; 157(2):239–243.
   PubMed Web of Science ®Google Scholar
• Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S: Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. Jama 2003; 289(1): 56–64.
   PubMed Web of Science ®Google Scholar
• Ellison JM, DeLuca P: Fluoxetine-induced genital anesthesia relieved by Ginkgo biloba extract. J Clin Psychiatry 1998; 59(4):199–200.
   PubMed Web of Science ®Google Scholar
• Jacobsen FM: Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992; 53(4):119–122.
   Google Scholar
• Ashton AK, Rosen RC: Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 1998; 59(3):112–115.
   PubMed Web of Science ®Google Scholar
• Labbate LA, Grimes JB, Hines A, Pollack MH: Bupropion treatment of serotonin reuptake antide-pressant-associated sexual dysfunction. Ann Clin Psychiatry 1997; 9(4):241–245.
   Google Scholar
• Cohen AJ, Bartlik B: Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther 1998; 24(2): 139–143.
   PubMed Web of Science ®Google Scholar
• Ashton AK, Ahrens K, Gupta S, Masand PS: Antidepressant-induced sexual dysfunction and Ginkgo Biloba. Am J Psychiatry 2000; 157(5):836–837.
   Google Scholar
• Keller Ashton A, Hamer R, Rosen RC: Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: a large-scale retrospective study of 596 psychiatric outpatients. J Sex Marital Ther 1997; 23(3): 165–175.
   Google Scholar
• Landen M, Eriksson E, Agren H, Fahlen T: Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1999; 19(3):268–271.
   PubMed Web of Science ®Google Scholar
• Price D: Sildenafil (Viagra): Efficacy in the treatment of erectile dysfunction (ED) in patients with common concomitant conditions. J Impot Res 1998; 10:584.
   Google Scholar
• Fava M, Rankin MA, Alpert JE, Nierenberg AA, Worthington JJ: An open trial of oral sildenafilin antidepressant-induced sexual dysfunction. Psychother Psychosom 1998; 67(6):328–331.
   PubMed Web of Science ®Google Scholar
• Sacchetti E, Guarneri L, Bravi D: H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 2000; 48(2): 167–168.
   PubMed Web of Science ®Google Scholar
• Floris M, Lejeune J, Deberdt W: Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol 2001; 11(2): 181–182.
   Google Scholar
• Pace-Schott EE, Gersh T, Silvestri R, Stickgold R, Salzman C, Hobson JA: SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects. J Sleep Res 2001; 10(2): 129–142.
   Google Scholar
• Koponen H, Lepola U, Leinonen E, Jokinen R, Penttinen J, Turtonen J: Citalopram in the treatment of obsessive-compulsive disorder: An open pilot study. Acta Psychiatr Scand 1997; 96(5):343–346.
   Google Scholar
• Dilsaver SC, Greden JF: Antidepressant withdrawal phenomena. Biol Psychiatry 1984; 19(2):237–256.
   Google Scholar
• Hoehn-Saric R, Lipsey JR, McLeod DR: Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol 1990; 10(5): 343–345.
   PubMed Web of Science ®Google Scholar
• Price J, Grunhaus LJ: Treatment of clomipramine-induced anorgasmia with yohimbine: A case report. J Clin Psychiatry 1990; 51(1):32–33.
   PubMed Web of Science ®Google Scholar
• Reynolds RD: Sertraline-induced anorgasmia treated with intermittent nefazodone. J Clin Psychiatry 1997; 58(2):89.
   Google Scholar
• Lauerma H: Successful treatment of citalopram-induced anorgasmia by cyproheptadine. Acta Psychiatr Scand 1996; 93(1):69–70.
   Google Scholar
• Nelson EB, Keck PE, Jr., McElroy SL: Resolution of fluoxetine-induced sexual dysfunction with the 5-HT3 antagonist granisetron. J Clin Psychiatry 1997; 58(11):496–497.
   Google Scholar
• Balon R: Intermittent amantadine for fluoxetine-induced anorgasmia. J Sex Marital Ther 1996; 22(4): 290–292.
   PubMed Web of Science ®Google Scholar
• Sporn J, Ghaemi SN, Sambur MR, Rankin MA, Recht J, Sachs GS, Rosenbaum JF, Fava M: Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000; 12(3):137–140.
   PubMedGoogle Scholar
• Labbate LA, Pollack MH: Treatment of fluoxetine-induced sexual dysfunction with bupropion: A case report. Ann Clin Psychiatry 1994; 6(1):13–15.
   PubMedGoogle Scholar
• Bartlik BD, Kaplan P, Kaplan HS: Psychostimulants apparently reverse sexual dysfunction secondary to selective serotonin re-uptake inhibitors. J Sex Marital Ther 1995; 21(4):264–271.
   PubMed Web of Science ®Google Scholar
• Nurnberg HG, Lauriello J, Hensley PL, Parker LM, Keith SJ: Sildenafil for iatrogenic serotonergic antide-pressant medication-induced sexual dysfunction in 4 patients. J Clin Psychiatry 1999; 60(1):33–35.
   PubMed Web of Science ®Google Scholar
• Schaller JL, Behar D: Sildenafil citrate for SSRI-induced sexual side effects. Am J Psychiatry 1999; 156(1):156–157.
   Google Scholar
• Maclde M, Kocsis J. Effects on body weight of the SSRI citalopram. Presented at the American College of Neuropsychopharmacology meeting; 1998; Puerto Rico.
   Google Scholar
• Jefferson Jw, Greist JH. A double-blind comparison of citalopram and paroxetine in the treatment of patients with depression and anxiety. Presented at the American College of Neuropsychopharmacology meeting; 2000; San Juan, Puerto Rico.
   Google Scholar
• Thase ME, Bartlett C. Lack of weight gain during long-term therapy with the novel antipressant reboxetine. APA Annual Meeting; 2001; New Orleans, LA.
   Google Scholar
• Masand PS, Ashton A, Gupta S, et al. A double-blind, placebo-controlled trial of bupropion SR for SSRI-induced sexual dysfunction. 38th Annual Meeting of the ACNP; 1999; Acapulco, Mexico.
   Google Scholar
• Clayton ALM, McGarvey EL, Warnock JK, et al. Bupro-pion sustained release as an antidote to SSRI-induced sexual dysfunction. APA Annual Meeting; 2001; New Orleans, LA.
   Google Scholar